| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib
|
Tarantino, P.
|
|
|
33 |
8 |
p. 845-847
|
artikel
|
| 2 |
Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference
|
Launay, M.
|
|
|
33 |
8 |
p. 850-852
|
artikel
|
| 3 |
Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
|
Hughes, B.G.M.
|
|
|
33 |
8 |
p. 853
|
artikel
|
| 4 |
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
|
Van Baelen, K.
|
|
|
33 |
8 |
p. 769-785
|
artikel
|
| 5 |
Deciphering radiological stable disease to immune checkpoint inhibitors
|
Luo, J.
|
|
|
33 |
8 |
p. 824-835
|
artikel
|
| 6 |
Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression
|
Ngo, C.
|
|
|
33 |
8 |
p. 848-850
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
33 |
8 |
p. iii
|
artikel
|
| 8 |
Epstein–Barr virus DNA detection by targeted sequencing in post-treatment plasma samples and prognosis of locally advanced nasopharyngeal cancer: implications for clinical research
|
Economopoulou, P.
|
|
|
33 |
8 |
p. 747-749
|
artikel
|
| 9 |
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|
Pascual, J.
|
|
|
33 |
8 |
p. 750-768
|
artikel
|
| 10 |
First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report
|
Zhang, F.L.
|
|
|
33 |
8 |
p. 847-848
|
artikel
|
| 11 |
Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasma
|
Chan, D.C.T.
|
|
|
33 |
8 |
p. 794-803
|
artikel
|
| 12 |
Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial
|
Jimenez-Fonseca, P.
|
|
|
33 |
8 |
p. 786-793
|
artikel
|
| 13 |
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
|
Bakouny, Z.
|
|
|
33 |
8 |
p. 836-844
|
artikel
|
| 14 |
Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials ☆
|
Rischin, D.
|
|
|
33 |
8 |
p. 804-813
|
artikel
|
| 15 |
Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?
|
Glynne-Jones, R.
|
|
|
33 |
8 |
p. 745-746
|
artikel
|
| 16 |
Table of Contents
|
|
|
|
33 |
8 |
p. i-ii
|
artikel
|
| 17 |
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
|
Marczyk, M.
|
|
|
33 |
8 |
p. 814-823
|
artikel
|
Tijdschrift beschrijving